Publicaciones en las que colabora con MARÍA DEL CARMEN NÚÑEZ CARRETERO (24)

2013

  1. Chromatographic enantioresolution of six purine derivatives endowed with anti-human breast cancer activity

    Chromatographia, Vol. 76, Núm. 9-10, pp. 475-482

  2. Enantiospecific synthesis of heterocycles linked to purines: Different apoptosis modulation of enantiomers in breast cancer cells

    Current Medicinal Chemistry, Vol. 20, Núm. 38, pp. 4924-4934

  3. Uso de Scifinder como complemento para el desarrollo de la asignatura de química orgánica II del grado de farmacia y su aplicación a la investigación básica de laboratorio (PID 11-267)

    Innovación docente y buenas prácticas en la Universidad de Granada.: Vol. 2 (Editorial Universidad de Granada), pp. 1421-1431

2012

  1. Synthesis, unambiguous chemical characterization, and reactivity of 2,3,4,5-tetrahydro-1,5-benzoxazepines-3-ol

    RSC Advances, Vol. 2, Núm. 33, pp. 12631-12635

2011

  1. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors

    Current Medicinal Chemistry, Vol. 18, Núm. 7, pp. 943-963

  2. Syntheses of 2,3-dihydro-1,4-benzodioxins and bioisosteres as structural motifs for biologically active compounds

    Current Organic Chemistry, Vol. 15, Núm. 6, pp. 869-887

  3. Synthesis and anticancer activity of (RS)-9-(2,3-dihydro-1,4- benzoxaheteroin-2-ylmethyl)-9H-purines

    European Journal of Medicinal Chemistry, Vol. 46, Núm. 9, pp. 3795-3801

2010

  1. Synthesis of purine derivatives as scaffolds for a diversity of biological activities

    Current Organic Chemistry, Vol. 14, Núm. 20, pp. 2463-2482

2009

  1. Acyclonucleosides, modified seco-nucleosides, and salicyl- or catechol-derived acyclic 5-fluorouracil O,N-acetals: Antiproliferative activities, cellular differentiation and apoptosis

    Current Medicinal Chemistry, Vol. 16, Núm. 9, pp. 1166-1183

  2. Homochiral drugs: A demanding tendency of the pharmaceutical industry

    Current Medicinal Chemistry, Vol. 16, Núm. 16, pp. 2064-2074

2008

  1. Design, synthesis and anticancer activity against the MCF-7 cell line of benzo-fused 1,4-dihetero seven- and six-membered tethered pyrimidines and purines

    Current Medicinal Chemistry, Vol. 15, Núm. 25, pp. 2614-2631

  2. Regiospecific microwave-assisted synthesis and cytotoxic activity against human breast cancer cells of (RS)-6-substituted-7- or 9-(2,3-dihydro-5H-1,4-benzodioxepin-3-yl)-7H- or -9H-purines

    European Journal of Medicinal Chemistry, Vol. 43, Núm. 8, pp. 1742-1748

  3. Synthesis and anticancer activity of (R,S)-9-(2,3-dihydro-1,4-benzoxathiin- 3-ylmethyl)-9H-purines

    ChemMedChem, Vol. 3, Núm. 1, pp. 127-135

2007

  1. 6′-Chloro-7- or 9-(2,3-dihydro-5H-4,1-benzoxathiepin-3-yl)-7H- or 9H-purines and their corresponding sulfones as a new family of cytotoxic drugs

    Tetrahedron, Vol. 63, Núm. 1, pp. 183-190

  2. A synthetic uracil derivative with antitumor activity through decreasing cyclin D1 and Cdk1, and increasing p21 and p27 in MCF-7 cells

    Breast Cancer Research and Treatment, Vol. 105, Núm. 3, pp. 237-246

  3. QSAR as a tool for the development of potent antiproliferative agents by inhibition of choline kinase

    Current Computer-Aided Drug Design, Vol. 3, Núm. 4, pp. 297-313

2006

  1. Synthesis and anticancer activity studies of novel 1-(2,3-dihydro-5H-1,4-benzodioxepin-3-yl)uracil and (6′-substituted)-7- or 9-(2,3-dihydro-5H-1,4-benzodioxepin-3-yl)-7H- or 9H-purines

    Tetrahedron, Vol. 62, Núm. 50, pp. 11724-11733

2003

  1. Anticancer bisquaternary heterocyclic compounds: A ras-ional design

    Farmaco, Vol. 58, Núm. 3, pp. 221-229

  2. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells

    Oncogene, Vol. 22, Núm. 55, pp. 8803-8812

  3. QSAR-derived Choline Kinase inhibitors: How rational can antiproliferative drug design be?

    Current Medicinal Chemistry, Vol. 10, Núm. 13, pp. 1095-1112